The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis.
(2025) Kidney International — Vol. 108, n° 4, p. 686-694 (2025)
Files
FishbaneetalTherandomizedDIALIZE-Outcomestrial.pdf
Open Access - Adobe PDF
- 815.52 KB
Details
- Authors
- Abstract
- Patients receiving maintenance hemodialysis frequently experience predialysis hyperkalemia, with associated arrhythmias and cardiovascular events. The DIALIZE-Outcomes trial evaluated the effect of sodium zirconium cyclosilicate (SZC) on arrhythmia-related cardiovascular outcomes. Adults receiving thrice-weekly hemodialysis with predialysis hyperkalemia (serum potassium was 5.5 mmol/l or more) were randomized 1:1 to SZC (5 g once daily on nondialysis days, then titrated weekly over 4 weeks between 0 and 15 grams to attain normokalemia [serum potassium 4.0-5.0 mmol/l]) or placebo. The primary outcome was a composite end point of sudden cardiac death, stroke, or arrhythmia-related hospitalization, intervention, or emergency department visit. Secondary end points included individual cardiovascular outcomes from the primary composite end point, and those reflecting serum potassium control. Safety was evaluated throughout. Overall, 2690 participants were randomized. The trial was terminated early due to low event rates (∼33% of planned) and high study medication discontinuation rates, limiting generalizability of the results. No treatment effect was observed on the primary composite end point (SZC, 8.8% [119 patients] vs. placebo, 8.9% [119 patients]; hazard ratio 0.98; 95% confidence interval 0.76-1.26) or individual cardiovascular outcomes. Maintenance of normokalemia at 12 months was significantly better with SZC than placebo (74.0% [495 patients] vs. 47.0% [293 patients]; odds ratio 3.36; 95% confidence interval 2.64-4.26). Serious adverse events occurred in 38.6% (SZC) and 37.6% (placebo) of participants; hypokalemia occurred in 3.0% (SZC) and 1.4% (placebo). SZC did not demonstrate a treatment effect on arrhythmia-related cardiovascular outcomes despite efficacy on serum potassium control. Registered at ClinicalTrials.gov with study number NCT04847232.
- Affiliations
Citations
Fishbane, S., Dember, L. M., Jadoul, M., Kovesdy, C. P., Guzman, N., Kordzakhia, G., Lisovskaja, V., Sekar, P., Wessman, P., Al-Shurbaji, A., & Herzog, C. A. (2025). The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis. Kidney International, 108(4), 686-694. https://doi.org/10.1016/j.kint.2025.06.016 (Original work published 2025)